BackLixte Biotechnology Holdings Overview

Lixte Biotechnology Holdings Other Current Liabilities

Latest other current liabilities for LIXT: $560K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$559232.00
25.68% YoYΔ $114259.00 vs prior year quarter

Peer trimmed avg / median

Loading

Lixte Biotechnology Holdings Other Current Liabilities History

Loading

Lixte Biotechnology Holdings vs. peers: Other Current Liabilities Comparison

Loading

Lixte Biotechnology Holdings Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lixte Biotechnology Holdings (LIXT) FAQ

Lixte Biotechnology Holdings (LIXT) currently reports a other current liabilities of $560K as of June 2026. That compares with $440K in the prior-year period — up 25.7% year over year. Use the charts on this page to explore Lixte Biotechnology Holdings's other current liabilities history and peer comparisons.

Lixte Biotechnology Holdings's other current liabilities increased from $440K to $560K — a 25.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lixte Biotechnology Holdings reported $560K in other current liabilities as of June 2026. That compares with $440K in the prior-year period — up 25.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $560K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lixte Biotechnology Holdings, and consider following LIXT for alerts when major investors trade the stock.

Lixte Biotechnology Holdings is classified in the Healthcare sector. On other current liabilities, it currently shows $560K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIXT with unrelated industries.